FDMT 4D Molecular Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 12 May 2022 4D Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

   EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, reported first quarter 2022 financial results and provided corporate updates.
   

   "We made significant progress in the first quarter of this year in moving several key programs of our diverse pipeline of clinical-stage genetic medicines," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. "In January, we announced treatment of the first patient with 4D-150 for wet AMD, and in February we presented compelling initial clinical data on 4D-310 for Fabry disease at the WORLD Symposium. In addition, we reported treatment…

   View Full Article
2. 05 May 2022 4D Molecular Therapeutics to Participate in the BofA Securities 2022 Healthcare Conference

   EMERYVILLE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that management will participate in the 2022 Bank of America Healthcare Conference on Tuesday, May 10^th. Details of the fireside chat are as follows:
   

   Event: BofA Securities 2022 Healthcare Conference

   Date & Time: Tuesday, May 10, 2022 at 8:40 a.m. PT

   A live audio webcast of the presentation will be available by visiting the "Investors & Media" section of the 4DMT website at www.4dmoleculartherapeutics.com. A replay of the webcast will be available for at least two weeks following the live event.

   About 4DMT

   4DMT…

   View Full Article
3. 04 April 2022 4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-710, an A101 AAV Vector-based, Aerosol-delivered Genetic Medicine for the Treatment of Cystic Fibrosis

   EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (NASDAQ:FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that the first patient has been dosed in its Phase 1/2 clinical trial of 4D-710 in patients with cystic fibrosis.
   

   "The dosing of the first patient in the 4D-710 Phase 1/2 clinical trial in cystic fibrosis marks an important milestone for our company and for the patients we aim to benefit," said Robert Fishman, M.D., Chief Medical Officer and Pulmonology Therapeutic Area Head of 4DMT. "4D-710 utilizes the aerosol-delivered A101 vector developed at 4DMT through our proprietary Therapeutic Vector Evolution platform…

   View Full Article
4. 28 March 2022 4D Molecular Therapeutics Reports Full Year 2021 Financial Results and Operational Highlights

   • Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary evidence of clinical activity
     
   • Advanced two additional programs into clinical development: R100 vector-based 4D-150 for wet AMD, and A101 vector-based 4D-710 for cystic fibrosis
     
   • Initiated expansion of our GMP manufacturing facilities for potential commercial-scale clinical manufacturing capabilities
     
   • $315 million in cash, cash equivalents and investments at end of 2021 expected to fund operations into the second half of 2024

   EMERYVILLE, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), a clinical-stage biotherapeutics…

   View Full Article
5. 22 February 2022 4D Molecular Therapeutics Announces Resignation of Professor David Schaffer, Ph.D. from the Company's Board of Directors

   EMERYVILLE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies announced that Professor David Schaffer, Ph.D. has resigned as a director of 4D Molecular Therapeutics.
   

   Professor Schaffer's transition coincides with the evolution of 4DMT into a clinical-stage gene therapy company with five products in clinical development and plans to develop pre-commercial and late-stage clinical-regulatory capabilities, in addition to our on-going internal vector invention and GMP manufacturing platforms. Professor Schaffer was recently appointed Director of California Institute for Quantitative Biosciences (QB3) at…

   View Full Article